Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Offer Update - Court sanction of the Scheme

21 Dec 2011 10:49

RNS Number : 4085U
Investec PLC
21 December 2011
 



Investec Limited

Incorporated in the Republic of South Africa

Registration number 1925/002833/06

JSE share code: INL

ISIN: ZAE000081949

Investec plc

Incorporated in England and Wales

Registration number 3633621

JSE share code: INP

ISIN: GB00B17BBQ50

 

(jointly "Investec")

 

As part of the dual listed company structure, Investec plc and Investec Limited notify both the London Stock Exchange and the JSE Limited of matters which are required to be disclosed under the Disclosure, Transparency and Listing Rules of the United Kingdom Listing Authority (the "UKLA") and/or the JSE Listing Requirements.

 

Accordingly, we advise of the following:

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

21 December 2011

The Evolution Group Plc ("Evolution" or the "Company")

Offer Update - Court sanction of Scheme of arrangement

On 9 September 2011, the Evolution Directors and the Board of Directors of Investec plc ("Investec") announced that they had reached agreement on the terms of a recommended share offer ("the Offer"), to be implemented by way of a Court sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"), under which it was proposed that Investec would acquire the entire issued ordinary share capital of Evolution. A scheme document to shareholders of Evolution (the "Scheme Document"), containing further information on the Scheme, was published on 3 October 2011. The Scheme and its implementation was approved by the shareholders of Evolution on 27 October 2011.

Investec and Evolution are pleased to announce that the Court has today made an order to sanction the Scheme to give effect to the Offer. The Scheme will become effective on delivery of the Court order to the Registrar of Companies, which is expected to take place on 22 December 2011, whereupon the entire issued ordinary share capital of Evolution will be owned by Investec.

A request has been made to the UK Listing Authority and the London Stock Exchange for a suspension of the listing of, and dealings in, Evolution Shares with effect from 4.30 p.m. today, 21 December 2011. Evolution Shareholders on the register at the Scheme Record Time, being 6.00 p.m. on 21 December 2011, will receive 0.23124 New Investec Shares for each Scheme Share held.

Admission of the New Investec Shares to listing on the Official List of the UK Listing Authority (the "Official List") and to trading on the London Stock Exchange's main market for listed securities (the "Main Market") and the Johannesburg Stock Exchange is expected to occur with effect from 8.00 a.m. (UK time) tomorrow, 22 December 2011.

Settlement of the New Investec Shares held through CREST is expected to take place by 8.00 a.m. (UK time) tomorrow, 22 December 2011. Share certificates in relation to the New Investec Shares to be held in certificated form will be despatched no later than 5 January 2012.

The admission to trading of Evolution Shares on the Main Market and the listing of Evolution Shares on the Official List is expected to be cancelled at Evolution' request with effect from 8.00 a.m.(UK time) tomorrow, 22 December 2011.

Defined terms used but not defined in this announcement have the meanings set out in the Scheme Document.

Enquiries:

Evolution

Alex Snow

 

+44 (20) 7071 4300

 

Investec

Ursula Nobrega

Stephen Koseff

Bernard Kantor

 

+44 (20) 7597 5546

 

Credit Suisse (Financial Adviser to Evolution)

George Maddison

Joe Hannon

 

+44 (20) 7888 8888

 

Investec Investment Banking (Financial Adviser and Joint Corporate Broker to Investec)

David Currie

Christopher Baird

James Ireland

 

+44 (20) 7597 5970

 

Pelham Bell Pottinger (Financial PR to Evolution)

Victoria Geoghegan

 

+44 (20) 7861 3925

 

Citigate Dewe Rogerson (Financial PR to Investec)

Tom Baldock

Justin Griffiths

+44 (20) 7638 9571

 

Credit Suisse, which is authorised and regulated in the UK by the Financial Services Authority, is acting exclusively for Evolution and no one else in connection with the Offer and this announcement and will not be responsible to anyone other than Evolution for providing the protections afforded to clients of Credit Suisse or for providing advice in connection with the Offer or any matter referred to herein.

Investec Investment Banking, a division of Investec Bank plc, which is authorised and regulated in the UK by the Financial Services Authority, is acting for Investec and no one else in connection with the Offer and this announcement and will not be responsible to anyone other than Investec for providing the protections afforded to clients of Investec Investment Banking or for providing advice in connection with the Offer or any matter referred to herein.

This announcement is for information purposes only and does not constitute an offer to sell or an invitation to purchase any securities or the solicitation of an offer to buy any securities, pursuant to the Offer or otherwise. This announcement has been prepared for the purpose of complying with English law and the City Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom.

The release, publication or distribution of this announcement in certain jurisdictions may be restricted by law. Persons who are not resident in the United Kingdom or who are subject to other jurisdictions should inform themselves of, and observe, any applicable requirements.

A copy of this announcement will be made available, free of charge, at www.evgplc.com and www.investec.com by no later than 12 noon (London time) on 22 December 2011.

You may request a hard copy of this announcement, free of charge, by contacting the Company Secretary of Evolution on +44 (20) 7071 4300. You may also request that all future documents, announcements and information to be sent to you in relation to the Offer should be in hard copy form.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPBFLFLFLFZFBD
Date   Source Headline
13th Dec 20177:00 amRNSCollaboration with King's College London
11th Dec 20177:15 amRNSHardman Res.: Funded to the end of Phase II trials
8th Dec 20177:15 amRNSPlacing and Notice of General Meeting
8th Dec 20177:00 amRNSInterim Results
23rd Nov 201711:05 amRNSSecond Price Monitoring Extn
23rd Nov 201711:00 amRNSPrice Monitoring Extension
4th Oct 20177:00 amRNSFirst European Patent Grant
31st Aug 20177:00 amRNSIssue of Equity and Total Voting Rights
2nd Aug 20171:00 pmRNSSFX-01 data published in Peer Reviewed Journal
27th Jul 20177:00 amRNSResult of AGM
26th Jul 20177:00 amRNSAGM Statement
11th Jul 201712:30 pmRNSCharity-funded Study of SFX-01 in TNBC
21st Jun 201710:00 amRNSPosting of Annual Report and AGM Notice
21st Jun 20177:15 amRNSHardman Research: Making clinical progress
13th Jun 20177:00 amRNSFull Year Results
1st Jun 20177:00 amRNSCompassionate Use Programme and Trials Update
25th May 20177:00 amRNSNotice of Preliminary Results
3rd Apr 20172:15 pmRNSDirectorate Change
28th Mar 20172:45 pmRNSFurther US Patent Grant
6th Mar 20177:00 amRNSIssue of Equity, PDMR Shareholding and TVR
14th Feb 20171:30 pmRNSPatent Grant in the United States
13th Feb 20177:00 amRNSServices Agreement with APTrans
17th Jan 20177:00 amRNSFirst Patient Dosed in Breast Cancer Trial
17th Jan 20177:00 amRNSAppointment of CFO and Head of Clinical Operations
11th Jan 20177:00 amRNSPositive DSMB Review of SAS Trial
5th Dec 20167:00 amRNSHalf Yearly Report
29th Nov 201611:53 amRNSHardman Research: Clinical sulforaphane potential
17th Nov 20167:00 amRNSNotice of Interim Results
1st Nov 201612:30 pmRNSGrant of Options
15th Sep 20167:00 amRNSUpdate re SFX-01 Data at ECTRIMS 2016
8th Sep 20163:30 pmRNSPresentation of SFX-01 Data at ECTRIMS 2016
24th Aug 20163:15 pmRNSOrphan Designation in the USA in SAH
17th Aug 20167:00 amRNSApproval for Phase II Study in Breast Cancer
24th Jun 20163:36 pmRNSResult of AGM
9th Jun 20167:00 amRNSGrant of Options
2nd Jun 20167:00 amRNSPosting of Annual Report and AGM Notice
31st May 20167:00 amRNSFinal Results
9th May 20167:00 amRNSNotification of Preliminary Results
3rd May 20167:00 amRNSFirst Patient Dosed in Phase II Trial
2nd Mar 20167:00 amRNSApproval of Phase II Clinical Trial in SAH
19th Jan 20163:23 pmRNSCorrection: Director Share Purchases
19th Jan 20167:00 amRNSDirector Share Purchases
11th Jan 20167:00 amRNSExercise of Options
4th Jan 20167:00 amRNSAppoints Chief Medical Officer
7th Dec 20157:00 amRNSHalf Yearly Report
23rd Nov 20157:00 amRNSExpands Pipeline with Novel Compounds
16th Nov 20157:00 amRNSNotification of Half Year Results
23rd Oct 201511:45 amRNSNotification of Major Interest in Shares
21st Oct 20157:00 amRNSFirst Day of Dealings
21st Dec 20114:30 pmRNSTemporary Suspension Evolution Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.